纳入分子检测能否提高先天性肾上腺皮质增生症新生儿筛查的准确性
该研究回顾性分析明尼苏达州新生儿筛查数据,比较传统类固醇两 tier 方案与纳入 CYP21A2 基因分子检测的多 tier 方案。传统方案筛查 68659 例活产儿,假阳性 91 例、假阴性 2 例、真阳性 1 例;分子多 tier 方案则假阳性 52 例、假阴性 0 例、真阳性 3 例。结论认为分子检测可提高筛查准确性,但实施前需考虑分子检测的独特挑战。
要点
- 传统类固醇两 tier 方案筛查 68659 例活产儿,假阳性 91 例、假阴性 2 例、真阳性 1 例。
- 分子多 tier 方案(更低一线切点、21 变异 panel、CYP21A2 测序)假阳性 52 例、假阴性 0 例、真阳性 3 例。
- 分子检测可提高 CAH 新生儿筛查准确性,但实施前需考虑其独特挑战。
核心结论
- 纳入分子检测可提高先天性肾上腺皮质增生症新生儿筛查的准确性,但实施前需考虑分子检测的独特挑战。
研究设计与样本
- 研究为为期 1 年的明尼苏达州新生儿筛查结果回顾性分析,事后比较传统类固醇两 tier 方案与分子多 tier 方案。
主要发现
- 对 103 个明尼苏达家庭进行 CYP21A2 基因测序,得到包含 21 个致病变异的明尼苏达特异性 panel。
- 美国疾病控制与预防中心创建的分子检测方法准确性和可重复性均为 100%。
- 传统类固醇两 tier 方案筛查 2015 年 68659 例活产儿,假阴性 2 例、假阳性 91 例、真阳性 1 例。
- 分子多 tier 方案(更低一线类固醇切点、二线 21 变异 CYP21A2 panel、三线 CYP21A2 测序)则假阴性 0 例、假阳性 52 例、真阳性 3 例。
关键数值与推荐
- 传统类固醇两 tier 方案:假阴性 2 例、假阳性 91 例、真阳性 1 例(68659 例活产儿)。
- 分子多 tier 方案:假阴性 0 例、假阳性 52 例、真阳性 3 例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Single-tier newborn screening (NBS) for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17OHP) measured by fluoroimmunoassay (FIA) in samples collected at 24 to 48 hours produces a high false-positive rate (FPR). Second-tier steroid testing can reduce the FPR and has been widely implemented. OBJECTIVE: We investigated the accuracy of an alternative multitier CAH NBS protocol that incorporates molecular testing of the CYP21A2 gene and reduces the first-tier 17OHP cutoff to minimize missed cases. METHODS: We create a Minnesota-specific CYP21A2 pathogenic variants panel; developed a rapid, high-throughput multiplex, allele-specific-primer-extension assay; and performed a 1-year retrospective analysis of Minnesota NBS results comparing metrics between a conventional steroid-based 2-tier protocol and a molecular-based multitier NBS protocol, applied post hoc. RESULTS: CYP21A2 gene sequencing of 103 Minnesota families resulted in a Minnesota-specific panel of 21 pathogenic variants. The Centers for Disease Control and Prevention created a molecular assay with 100% accuracy and reproducibility. Two-tier steroid-based screening of 68 659 live births during 2015 resulted in 2 false negatives (FNs), 91 FPs, and 1 true positive (TP). A 3-tier protocol with a lower first-tier steroid cutoff, second-tier 21-variant CYP21A2 panel, and third-tier CYP21A2 sequencing would have resulted in 0 FNs, 52 FPs, and 3 TPs. CONCLUSION: Incorporation of molecular testing could improve the accuracy of CAH NBS, although some distinct challenges of molecular testing may need to be considered before implementation by NBS programs.
引用
- Sarafoglou K, Gaviglio A, Wolf C, et al. Can Incorporating Molecular Testing Improve the Accuracy of Newborn Screening for Congenital Adrenal Hyperplasia? J Clin Endocrinol Metab. 2025. PMID: 38701341. doi:10.1210/clinem/dgae297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。